Molecular glue: Difference between revisions
CSV import Tags: Manual revert Reverted mobile edit mobile web edit |
No edit summary Tag: Manual revert |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 21: | Line 21: | ||
[[Category:Protein-Protein Interaction Modulators]] | [[Category:Protein-Protein Interaction Modulators]] | ||
{{pharmacology-stub}} | {{pharmacology-stub}} | ||
Latest revision as of 05:20, 3 March 2025
Molecular glue, also known as Protein-Protein Interaction Modulators, is a type of small molecule that facilitates the interaction between two proteins, often leading to the degradation of one of the proteins. This process is a key component of the body's Proteostasis mechanisms, which maintain the balance of proteins within cells.
Mechanism of Action[edit]
Molecular glue works by binding to a Target Protein and a Ubiquitin Ligase, bringing them into close proximity. This allows the ubiquitin ligase to attach a Ubiquitin molecule to the target protein, marking it for degradation by the Proteasome. This process is known as Ubiquitination.
Applications in Medicine[edit]
Molecular glue has significant potential in the field of Pharmacology, particularly in the development of new drugs. By targeting specific proteins for degradation, molecular glue can be used to treat diseases caused by the overproduction or malfunction of certain proteins. For example, molecular glue has been used in the development of drugs to treat Cancer, Neurodegenerative Diseases, and Autoimmune Diseases.
Examples of Molecular Glue[edit]
There are several known examples of molecular glue, including Thalidomide, Lenalidomide, and Pomalidomide. These drugs, known as Immunomodulatory Drugs, were originally developed to treat Multiple Myeloma, but have since been found to have broader applications due to their ability to degrade specific proteins.
Challenges and Future Directions[edit]
While molecular glue holds great promise, there are also significant challenges to its use. One major challenge is the difficulty of designing molecules that can bind to both the target protein and the ubiquitin ligase. Additionally, there is the risk of off-target effects, where the molecular glue degrades proteins other than the intended target. Despite these challenges, research into molecular glue continues, with the hope of developing more effective and targeted treatments for a range of diseases.
